About
Our passion is to find novel solutions for skin diseases.
Company
An engaging group of highly experienced, entrepreneurial-minded people make up Elorac. We are proud of what we do because we know it is making a difference in people’s lives.
Click Here For More Information
Dynamic Pharmaceutical Company
Our focus is finding better treatments for skin diseases. We were founded by dermatology professionals with a long and successful heritage of caring for the skin. Being deeply rooted in dermatology enables us to be responsive to the needs of this community. First-hand experience of the challenges and frustration of living with various cutaneous diseases fuels our passion to find novel solutions for the treatment of skin conditions that affect millions of people both physically and with many in their quality of life.
We blend our talent for discovery with extensive experience developing and commercializing prescription pharmaceutical products. Our rich pipeline of novel treatments represents potentially significant advances in the management of skin diseases.
Our personal and professional integrity permeates every aspect of the work we do:
- We improve the lives of our patients
- We share responsibility and hold our people accountable
- We drive innovation and embrace change
- We hire, develop, and reward high performance people
- We plan and execute with professionalism and thoroughness
- We build shareholder value
It’s what we believe in.
Management Team
Proven Record of Accomplishment
Elorac’s Leadership Team –
- Collectively accumulated more than 120 years of dermatology experience.
- Filed more than 150 patents.
- Authored/co-authored more than 125 scientific publications.
- Built 6 dermatology sales teams.
- Submitted more than 10 approved NDAs.
- Launched more than 100 dermatology products with cumulative sales in excess of $1 billion.
- Founded or co-founded pharmaceutical companies that were sold for more than $1 billion in the aggregate.
About Our Management Team
Joel E. Bernstein, M.D.
Executive Chairman
Joel E. Bernstein, M.D. is the founder and Executive Chairman of Elorac. Before starting Elorac, Dr. Bernstein was the founder, Chairman, and Chief Executive Officer of GenDerm Corporation, a pharmaceutical company that was acquired by Medicis Pharmaceutical Corporation in 1997. Previously, Dr. Bernstein was head of dermatopharmacology at Northwestern University Medical School and the University of Chicago Pritzker School of Medicine. Dr. Bernstein has also held senior scientific positions at Abbott Laboratories and Schering-Plough Corporation. He has authored more than 125 scientific publications and holds over 150 patents. Dr. Bernstein received a B.A. from Carleton College and an M.D. from the University of Chicago Pritzker School of Medicine, where he received the Roche Award for ranking first in his class. He completed specialty-training programs in both dermatology and clinical pharmacology at the University of Chicago. Dr. Bernstein is a past president of the University of Chicago Medical and Biological Alumni Association. In 1988, he was chosen as Illinois high-tech entrepreneur of the year. Dr. Bernstein was also the founder and non-executive chairman of Sirius Laboratories, Inc., a dermatologic products company acquired by DUSA Pharmaceuticals in 2006.
Jeffrey Bernstein, Ph.D.
President & Chief Executive Officer
Jeffrey Bernstein, Ph.D., CFA is the President & Chief Executive Officer of Elorac, Inc. He has over 10 years experience at entrepreneurial pharmaceutical companies in executive and board positions, notably as a director of Sirius Laboratories and as Chief Operating Officer, Chief Financial Officer, and a director of Winston Laboratories. He crafted the original business plan of Elorac and provided strategic counsel on business development opportunities. Prior to entering the pharmaceutical industry, Dr. Bernstein was an assistant professor of economics and public policy at the University of Wisconsin-Madison. He received a B.A. in economics summa cum laude from Amherst College and a Ph.D. in business economics from Harvard University.
Barry Hollingsworth
Chief Financial Officer
Barry Hollingsworth, CPA, CFA has been our CFO/Controller since 2009. He is responsible for financial strategy of the corporation including corporate finance, treasury, tax, mergers & acquisitions, banking and insurance relationships and other strategic aspects of the business. Prior to his role at Elorac, Barry was CFO of the Parent Company, based in Denver from 2007 through 2008. From 2005 through 2007, Mr. Hollingsworth was CFO of Stratos International, a technology company based in Chicago. Mr. Hollingsworth holds a Bachelor’s degree from Northern Illinois University and a Master’s in Business Administration from DePaul University. Mr. Hollingsworth is a Certified Public Accountant licensed in Illinois and holds the Chartered Financial Analyst designation. He is a member of the American Institute of Certified Public Accountants, the Illinois CPA Society and the CFA Society of Chicago.
Scott B. Phillips, M.D.
Senior Vice President, Scientific Affairs
Scott B. Phillips, M.D. is Senior Vice President, Scientific Affairs. Previously Director of Drug Discovery at GenDerm Corporation and Senior Vice President, Scientific Affairs at Winston Pharmaceuticals. Dr. Phillips has 23 years of experience in the pharmaceutical industry. In addition, he has been Chief of the Clinical Investigations Unit at Harvard Medical School and Clinical Assistant Professor of Dermatology and Medicine at the University of Chicago Pritzker School of Medicine. He received a B.A. in biology from Cornell University and an M.D. from Harvard University.
Board Of Directors
- Joel E. Bernstein, M.D.
Executive Chairman of the Board - Jeffrey Bernstein, Ph.D.
President & Chief Executive Officer - Robert Essner
- Keymours Soltani, M.D.
- Robert A. Yolles, J.D.
- David Whitney, M.D.
About Our Board of Directors
Joel E. Bernstein, M.D.
Executive Chairman of the Board
Joel E. Bernstein, M.D. is the founder and Executive Chairman of Elorac. Before starting Elorac, Dr. Bernstein was the founder, Chairman, and Chief Executive Officer of GenDerm Corporation, a pharmaceutical company that was acquired by Medicis Pharmaceutical Corporation in 1997. Previously, Dr. Bernstein was head of dermatopharmacology at Northwestern University Medical School and the University of Chicago Pritzker School of Medicine. Dr. Bernstein has also held senior scientific positions at Abbott Laboratories and Schering-Plough Corporation. He has authored more than 125 scientific publications and holds over 150 patents. Dr. Bernstein received a B.A. from Carleton College and an M.D. from the University of Chicago Pritzker School of Medicine, where he received the Roche Award for ranking first in his class. He completed specialty-training programs in both dermatology and clinical pharmacology at the University of Chicago. Dr. Bernstein is a past president of the University of Chicago Medical and Biological Alumni Association. In 1988, he was chosen as Illinois high-tech entrepreneur of the year. Dr. Bernstein was also the founder and non-executive chairman of Sirius Laboratories, Inc., a dermatologic products company acquired by DUSA Pharmaceuticals in 2006.
Jeffrey Bernstein, Ph.D.
President & Chief Executive Officer
Jeffrey Bernstein, Ph.D., CFA is the President & Chief Executive Officer of Elorac, Inc. He has over 10 years experience at entrepreneurial pharmaceutical companies in executive and board positions, notably as a director of Sirius Laboratories and as Chief Operating Officer, Chief Financial Officer, and a director of Winston Laboratories. He crafted the original business plan of Elorac and provided strategic counsel on business development opportunities. Prior to entering the pharmaceutical industry, Dr. Bernstein was an assistant professor of economics and public policy at the University of Wisconsin-Madison. He received a B.A. in economics summa cum laude from Amherst College and a Ph.D. in business economics from Harvard University.
Robert Essner
Robert Essner is former chairman and CEO of Wyeth, one of the world’s leading research-based pharmaceutical companies. He led the transformation of Wyeth into a science-based industry leader with strong positions in drugs, biotechnology, vaccines, nonprescription products and animal health. During his more than 30 years in the industry, Mr. Essner served as chairman of both U.S. and global pharmaceutical organizations. He serves as adjunct professor of business at Columbia Business School. In addition, he serves on the board of MassMutual, NBTY, PPDI, Amicus Therapeutics, and the Children’s Health Fund, and is a Senior Advisor to The Carlyle Group. Mr. Essner is a graduate of Miami University and the University of Chicago.
Keymours Soltani, M.D.
Keyoumars Soltani, M.D. is currently Professor of Medicine and Director, Skin Surgery Clinic at The University of Chicago Medical Center and previously was Chairman of the Section of Dermatology at the University of Chicago. Dr. Keyoumars Soltani is an expert in surgery for dermatological conditions, including laser surgery and Mohs micrographic surgery. He specializes in the treatment of skin cancers, graft-versus-host disease (GVHD) and blistering conditions. Dr. Soltani’s research interests at the University of Chicago include the immunopathology of dermatological diseases. Dr. Soltani is Board Certified in Dermatology, Dermatopathology and Dermatological Immunology.
Robert A. Yolles, J.D.
Robert A. Yolles, J.D. is a Director of Elorac and a retired partner of the international law firm Jones Day. While a partner, he served as the chair of the Firm’s domestic and international finance practices and, previously, co-chair of the Firm’s corporate practice. He received a B.A. and J.D. from Northwestern University.
David Whitney, M.D.
David Whitney, M.D. is a Director of Elorac and has had a private dermatology practice in suburban Chicago since 1987. Prior to this he was Assistant Clinical Professor of Medicine and Director of the Dermatology Clinic at the University of Chicago. Dr. Whitney was a dermatology resident at the University of Chicago, and served as Chief Resident from 1983-1984. He is a member of the American Academy of Dermatology as well as a number of other dermatology organizations. Dr. Whitney was President of the University of Chicago Medical and Biological Alumni Association from 2004-2006 and is currently a member of the Visiting Committee To The Division of Biological Sciences and The Pritzker School of Medicine at the University of Chicago. Dr. Whitney received a B.A. from Rice University, and an M.D. and M.B.A. from the University of Chicago.